Align Technology, Inc. — 6.55/10

HOLD
NASDAQ: ALGN  |  Global #1 in clear aligners with >70% market share (Invisalign ~80% of revenue). Dominant oligopoly position in a secularly growing category (clear aligners taking share from metal braces, mid-teens+ CAGR). Volume genuinely accelerating (+6.8% Q1'26). But revenue growth chronically lags volume due to ASP/mix erosion. Gross margin compressed ~710bps from FY21 peak. FCF positive but declining -21% YoY.
Q1'26 Revenue
+6.2% YoY | Re-accelerating
Global Aligner Share
>70%
Near-monopoly at premium tier | Oligopoly PASS
FY2025 FCF
-21% YoY | Declining
Forward P/E
~15.7x
vs ~18-20x med-tech peers | Below peer avg

Company stats
CEO Joe Hogan (since 2015) CFO John Morici (since 2017)
FY2025 Revenue $4,035M (+0.9% YoY) FY2025 Non-GAAP Op Margin 22.7%
Clear Aligner Rev $3,245M (80%) Systems & Services $790M (20%)
FYE December 31 Quality Gate Partial Pass (1 NO: FCF declining)

Score breakdown
5
/ 10
Financial Trends Weight: 25% | Weighted: 1.25
7
/ 10
Thematic Exposure Weight: 35% | Weighted: 2.45
8
/ 10
Management Quality Weight: 20% | Weighted: 1.60
4
/ 10
Investor Sentiment Weight: 5% | Weighted: 0.20
7
/ 10
Concerns & Risks Weight: 15% | Weighted: 1.05
Dimension Score Weight Weighted
Financial Trends 5 25% 1.25
Thematic Exposure 7 35% 2.45
Management Quality 8 20% 1.60
Investor Sentiment 4 5% 0.20
Concerns & Risks 7 15% 1.05
Composite 100% 6.55

Investment thesis

A dominant >70%-share clear-aligner leader run by a credible, deeply tenured beat-and-raise management team at a below-peer ~15.7x forward P/E with controllable self-help catalysts. Held back by stagnant economics: volume grows but ASP/mix erosion compresses margins and FCF fell 21%. No contrarian management-street wedge -- management actively suppresses its own upside narrative. Quality franchise, modest economics, no edge.

Quality gate: PARTIAL PASS (1 NO). Oligopoly = YES. Management track record = YES. Positive and growing FCF = NO.


Data sourced from Daloopa (company_id: 255). Analysis date: 2026-06-27.